Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782095 | 0.88 | KCNH2 (0.42) | MEN1KMT2ASIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL20782047 | 0.88 | SIGMAR1 (0.55) | DRD2MEN1KMT2ASIGMAR1KCNH2 | |
| SCHEMBL20782145 | 0.86 | ALDH1A1 (0.55) | KCNH2ALDH1A1TSHR | |
| SCHEMBL19567532 | 0.84 | CXCR3 (0.46) | CXCR3CHRM3DRD4DRD2OPRM1 | |
| SCHEMBL20781754 | 0.84 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL20782064 | 0.84 | CXCR3 (0.46) | CXCR3CHRM3DRD4DRD2OPRM1 | |
| SCHEMBL20782009 | 0.83 | ALDH1A1 (0.55) | SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL20781761 | 0.81 | SIGMAR1 (0.52) | CHRM3DRD2OPRM1MEN1KMT2A | |
| SCHEMBL20782262 | 0.81 | TACR1 (0.48) | CHRM3DRD4DRD2ALDH1A1 | |
| SCHEMBL20781756 | 0.81 | HTR2A (0.43) | OPRM1SIGMAR1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CXCR3 345/4885CHRM3 4680/4885DRD4 4881/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | CXCR3 345/4885CHRM3 4680/4885DRD4 4881/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CXCR3 345/4885CHRM3 4680/4885DRD4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.